Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
GSK1940029
Cat. No.:
OB0225LY-0224
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR and LC-MS.
Size:
Product Overview
Description:
GSK1940029 is a novel compound that shows modulatory effects on a variety of receptors and is mainly investigated for its function in the nervous system.
Synonym:
SCD inhibitor 1; 1150701-66-8; 1-[(3,4-Dichlorophenyl)methyl]-N-[4-(hydroxymethyl)phenyl]-5-methyltriazole-4-carboxamide; 1-[(3,4-Dichlorophenyl)methyl]-N-[4-(hydroxymethyl)phenyl]-5-methyl-H-1,2,3-triazole-4-carboxamide
CAS No.:
1150701-66-8
Compound CID:
42603008
Formula:
C18H16Cl2N4O2
Formula Weight:
391.25
Specification
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
GSK1940029 can be used in neuropharmacology studies or play an important role in mental health research.
Library Information
Targets:
Dehydrogenase; Stearoyl-CoA desaturase (SCD)
Pathways:
Metabolism
Plate Number:
AOCL-3
Plate Location:
g8
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
30 mg/mL; 76.67 mM
